This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Flett, A. S. Articles by Moon, J. C. Search for Related Content PubMed PubMed Citation Articles by Flett, A. S. Articles by Moon, J. C. Related Collections CT and MRI Cardiovascular imaging agents/Techniques

Advances in Cardiovascular Imaging

The Prognostic Implications of Cardiovascular Magnetic Resonance

Andrew S. Flett, MBBS; Mark A. Westwood, MBBS, MD; L. Ceri Davies, MBBS, MD; Anthony Mathur, MA, PhD and James C. Moon, MBBCh, MD

From the Department of Cardiology (A.S.F., J.C.M.), The Heart Hospital, Part of University College London Hospitals NHS Trust, London; the Department of Medicine (A.S.F., J.C.M.), University College London; and the Department of Cardiology (M.A.W., L.C.D., A.M.), The London Chest Hospital, Bonner Road, London, United Kingdom.

Correspondence to James Moon, MBBCh, MD, The Heart Hospital, 16-18 Westmoreland St, London W1G 8PH, United Kingdom. E-mail james.moon@uclh.nhs.uk

Key Words: outcomes • CMR • prognosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Noninvasive imaging modalities are changing the management of cardiovascular disease. Cardiovascular magnetic resonance (CMR) has matured as a clinical tool, having passed through validation, standardization, and clinical roll-out phases.^1–5 CMR now aids the prediction of clinical outcomes with a growing prognostic evidence base, systematically reviewed here with a summary of 32 CMR outcome studies with 8855 patients (range, n=25 to 1299). Ongoing trials on the clinicaltrials.gov website are also highlighted.

	Methods

 
The methodologies of systematic review were used with a search of electronic databases (PubMed, Medline) for studies published from 1998 to 2008 using key words in combination as both MeSH terms and text words. Major article references and the 2008 American Heart Association, American College of Cardiology, European Society of Cardiology (ESC), and Society for Cardiovascular Magnetic Resonance (SCMR) abstracts were also reviewed. In total, 32 CMR studies with outcome data (8855 patients, 22 253 patient-years) were included. In addition, more than 380 CMR trials registered on clinicaltrials.gov were reviewed for the presence of prognostic primary/secondary end points to indicate future research directions.

CMR in Ischemic Heart Disease
The assessment of ischemic heart disease (IHD) benefits from the multiplicity of techniques available within a single CMR study. Rest function is typically combined with the use of gadolinium chelate contrast agents in 3 postcontrast temporal phases: Perfusion (first pass) for microvascular obstruction (MVO, the tissue equivalent of no-reflow) and for ischemia, either at rest or during stress; early for MVO and thrombus detection; and late for focal interstitial expansion—the late gadolinium enhancement (LGE) technique for myocardial . . . [Full Text of this Article]